Colony Group’s Juno Therapeutics, Inc. JUNO Stock Holding History

Colony Group’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-750	Closed	-$33K	–	738
2015 Q4	$33K	Buy	750 +250	+50%	+$12.4K	﹤0.01%	524
2015 Q3	$20K	Hold	500	–	–	﹤0.01%	549
2015 Q2	$27K	Hold	500	–	–	﹤0.01%	522
2015 Q1	$30K	Buy	+500	New	+$24.3K	﹤0.01%	477

Other funds holding JUNO

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BCM

Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Colony Group's JUNO Position: Q1 2016 in Review

Colony Group sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2016, closing a stake of 750 shares — an estimated $33K sold.

Colony Group first reported a position in JUNO in Q1 2015 and held it in 4 quarters. The position peaked at $33K in Q4 2015. 158 funds tracked by Wall St. Rank hold JUNO as of Q1 2016.

Colony Group reported no remaining Juno Therapeutics, Inc. position as of Q1 2016 after selling out during the quarter.
Colony Group sold 750 Juno Therapeutics, Inc. shares in Q1 2016, an estimated $33K.
Colony Group first reported a position in Juno Therapeutics, Inc. in Q1 2015 and held it in 4 quarters.
Colony Group's Juno Therapeutics, Inc. position peaked at $33K in Q4 2015.
158 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2016.

Based on Colony Group's 13F filing for Q1 2016, filed 16 May 2016.